container

New Research Looks at Immunologic Therapy of Renal Cell Carcinoma

Oncology & Hematology Review, the peer-reviewed journal, publishes cutting-edge article on Immunologic Therapy of Renal Cell Carcinoma.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
While targeted therapies are applicable to most patients, improvements of median survival have been measured in months.

(PRWEB UK) 3 June 2014

Oncology & Hematology Review, the peer-reviewed journal, publishes cutting-edge article on Immunologic Therapy of Renal Cell Carcinoma.

Interleukin-2 (IL-2) has been the mainstay of immunotherapy of metastatic renal cell carcinoma (mRCC) therapy for over 20 years. Although IL-2 treatment is limited to fit patients, a select group of these patients have derived substantial, durable benefit from it, for some translating into cures with no ongoing therapy or chronic toxicity. While targeted therapies are applicable to most patients, improvements of median survival have been measured in months. Immunotherapy, encompassing not only IL-2 but also newer checkpoint and vaccine approaches, therefore still has an important role for many as a main choice in RCC treatment. Enhanced patient selection techniques have evolved over time, and the overall response rate to high-dose (HD) IL-2 has improved among those selected patients. An increased understanding of immunotherapy has led to other novel approaches. These include checkpoint inhibitors mediating changes of T-cell behavior acting at the lymphocyte protein receptor programmed death-1 (PD-1), such as nivolumab, and vaccine immunotherapies, including peptide and dendritic cell vaccines in pivotal trials, and coordinated use of radiation therapy with IL-2, encouraging in early phase testing. Such approaches have the potential to expand the immune approach to achieve outcomes with better overall survival for many patients with mRCC.

To continue reading this peer-reviewed article in full for free please go to: http://www.touchoncology.com/articles/immunologic-therapy-renal-cell-carcinoma.

NOTE TO EDITORS:
touchONCOLOGY (a division of Touch Medical Media) provides independent, cutting-edge, peer-reviewed content from world renowned physicians, designed to lead the debate on health and to engage, inform, and support physicians in improving patient outcomes globally.

touchONCOLOGY.com provides an international platform for peer-reviewed content from industry-leading journals alongside other carefully selected sources and aims to support physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity within the field of oncology.

Our portfolio of peer-reviewed journals, European Oncology & Haematology and Oncology & Hematology Review comprise of concise review articles which are designed to keep busy physicians up-to-date with the latest developments in their field and serve as a key reference resource for the international oncology community.

http://www.touchONCOLOGY.com


Contact